The pathogenic process in Alzheimer's disease (AD) appears to be closely linked to the neurotoxic action of amyloid-β (Aβ) oligomers. Recent studies have shown that these oligomers bind with high affinity to the membrane-anchored cellular prion protein (PrP C ). It has also been proposed that this binding might mediate some of the toxic effects of the oligomers. Here, we show that the soluble (membrane anchor-free) recombinant human prion protein (rPrP) and its N-terminal fragment N1 block Aβ oligomers-induced inhibition of long-term potentiation (LTP) in hippocampal slices, an important surrogate marker of cognitive deficit associated with AD. rPrP and N1 are also strikingly potent inhibitors of Aβ cytotoxicity in primary hippocampal neurons. Furthermore, experiments using hippocampal slices and neurons from wild-type and PrP C null mice (as well as rat neurons in which PrP C expression was greatly reduced by gene silencing) indicate that, in contrast to the impairment of synaptic plasticity by Aβ oligomers, the cytotoxic effects of these oligomers, and the inhibition of these effects by rPrP and N1, are independent of the presence of endogenous PrP C . This suggests fundamentally different mechanisms by which soluble rPrP and its fragments inhibit these two toxic responses to Aβ. Overall, these findings provide strong support to recent suggestions that PrP-based compounds may offer new avenues for pharmacological intervention in AD.
Introduction
Alzheimer's disease (AD) is associated with the accumulation of extracellular amyloid plaques in the brain (Hardy and Selkoe, 2002; Selkoe, 2001) . The main component of these plaques is a 40-43 residue amyloid β (Aβ) peptide, a product of proteolytic processing of amyloid precursor protein. Even though Aβ plaques composed of amyloid fibrils are the neuropathological hallmark of the disease, a large body of evidence indicates that the main neurotoxic species are not mature plaques but smaller assemblies of Aβ, often referred to as soluble oligomers (Benilova et al., 2012; Hardy and Selkoe, 2002; Klein et al., 2001; Selkoe, 2001; Small et al., 2001; Walsh and Selkoe, 2007 ). The precise molecular structure of these oligomers and the mechanism by which they trigger pathogenic processes in AD are, however, largely unknown, hindering efforts to develop effective therapeutic strategies.
A recent important development was the finding that the cellular prion protein (PrP C ), an ubiquitous glycoprotein attached to the plasma membrane via the glycosylphosphatidylinositol (GPI) anchor can act as a receptor of Aβ oligomers (Lauren et al., 2009) . It was also proposed that this receptor plays a major role in AD pathogenesis, mediating neurotoxic effects of Aβ oligomers such as inhibition of long-term potentiation (LTP), neuronal cell death, and memory impairment on some mouse models of AD (Barry et al., 2011; Freir et al., 2011; Gimbel et al., 2010; Kostylev et al., 2015; Kudo et al., 2012; Lauren et al., 2009; Rushworth et al., 2013; Um et al., 2012) . Even though the notion of a critical role of PrP C as a mediator of Aβ toxicity in AD has been challenged in some other studies (Balducci et al., 2010; Calella et al., 2010;  Neurobiology of Disease 91 (2016) 124-131
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